Physiomics Plc

LSE PYC.L

Physiomics Plc EPS (Diluted) for the year ending June 30, 2024: USD -0.01

Physiomics Plc EPS (Diluted) is USD -0.01 for the year ending June 30, 2024, a 8.42% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Physiomics Plc EPS (Diluted) for the year ending June 30, 2023 was USD -0.01, a -96.47% change year over year.
  • Physiomics Plc EPS (Diluted) for the year ending June 30, 2022 was USD -0.00, a -4.06% change year over year.
  • Physiomics Plc EPS (Diluted) for the year ending June 30, 2021 was USD -0.00, a -172.61% change year over year.
  • Physiomics Plc EPS (Diluted) for the year ending June 30, 2020 was USD -0.00, a 37.21% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
SV Wall Street
LSE: PYC.L

Physiomics Plc

CEO Dr. Peter Joseph Sargent
IPO Date Dec. 20, 2004
Location United Kingdom
Headquarters The Magdalen Centre
Employees 11
Sector Health Care
Industries
Pharmaceuticals Biotechnology Research & Consulting
Description

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.

Similar companies

SAR.L

Sareum Holdings plc

USD 0.26

-4.52%

StockViz Staff

January 30, 2025

Any question? Send us an email